We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAILmediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASMdeficient splenocytes fail to cluster DR5 in ceramideenriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C 16 -ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.
Introduction
Members of the tumor necrosis factor (TNF) family of cytokines and receptors are critically involved in cellular activation, proliferation and death (Bhardwaj and Aggarwal, 2003; Fulda and Debatin, 2004) . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also called APO-2L is a member of the tumor necrosis factor family that appears to induce apoptosis predominantly in transformed cells (Wiley et al., 1995; Sheridan et al., 1997) , but also in some normal cells, for example stimulated splenocytes, memory or dendritic cells (Ursini- Siegel et al., 2002; Hayakawa et al., 2004; Janssen et al., 2005) . Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis by binding to one of the two death domain-containing TRAIL receptors, that is DR4 (TRAIL receptor 1) and DR5 (TRAIL receptor 2) (Sheridan et al., 1997) . In contrast to humans, mice do not seem to express a receptor homologous to DR4 and the mouse DR5-homolog seems to be the only death-inducing receptor of TRAIL (Wu et al., 1999) . Tumor necrosis factor-related apoptosis-inducing ligand also binds to the decoy receptors DcR1 (TRAIL-R3) (Sheridan et al., 1997) and DcR2 (TRAIL-R4) , but these receptors contain either no cytoplasmic death domain or a truncated death domain and, therefore, are unable to induce apoptosis. Finally, TRAIL interacts with osteoprotegerin, a secreted soluble protein; however, the functional significance of this interaction is less clear (Emery et al., 1998) . The current model of TRAIL signaling suggests that engagement of death receptors, that is DR4 and DR5, by the ligand leads to a recruitment of the cytoplasmic adapter protein FADD, which in turn activates caspase 8 (Mariani et al., 1997; Walczak et al., 1997) . Caspase 8 either directly activates downstream effector caspases 3, 6 and 7 (for a detailed review see Walczak and Krammer (2000) ), or the intrinsic mitochondria-mediated pathway through Bid cleavage (Yamada et al., 1999) , leading to the execution of apoptosis.
Tumor necrosis factor-related apoptosis-inducing ligand induces apoptosis in most tumour cells, while many normal tissues and cells, respectively, are relatively resistant to apoptosis (Ashkenazi et al., 1999; Walczak et al., 1999; Belka et al., 2004) . This finding created great interest and suggested TRAIL or anti-DR5 antibodies, respectively, as potential anticancer drugs (Fulda and Debatin, 2004) . Although TRAIL or DR5-antibodies showed only modest effects on experimental tumors, recent studies combining TRAIL with radiation or chemotherapeutic drugs, for example alkylphosphocholines or substances inducing DNAbreakage (Belka et al., 2001 (Belka et al., , 2004 Rohn et al., 2001; Jendrossek et al., 2002 Jendrossek et al., , 2003 El-Zawahry et al., 2005) revealed very effective induction of apoptosis and suggest that TRAIL or anti-DR5 antibodies might be used in combination with further chemotherapeutic drugs and/or irradiation.
Recent studies indicated that the organization of death receptors in the membrane after stimulation is central for the initiation of signaling via these receptors. For instance, the extracellular domain of CD95 contains a motif, the PLAD domain that mediates trimerization of CD95 and seems to contribute to the specificity of the interaction between CD95 ligand and CD95 . However, trimerization of the CD95 receptor is not sufficient to induce apoptosis (Schneider et al., 1998) and several studies demonstrated that CD95 signaling is initiated by oligomerization and aggregation (clustering), respectively, of the receptor in distinct domains of the cell membrane (Cremesti et al., 2001; Grassme et al., 2001a, b) .
Aggregation upon binding to the specific ligands has been reported for a large number of receptors including the TCR/CD3 complex (Boniface et al., 1998) , BCR (Graziadei et al., 1990) , CD40 (Vidalain et al., 2000) , FceR1 (Field et al., 1995) , CD95 (Schneider et al., 1998; Belka et al., 1999; Grassme et al., 2001b) , CD28 (Viola et al., 1999) , TNF-R , PDGFR (Liu et al., 1996) and CD2 (Rosenman et al., 1993) . Ligandinduced receptor clustering results in a high local density of the receptor, trans-activation of receptor-associating signaling molecules and a local assembly of the signaling elements of the activated receptor, which facilitate transduction of extracellular signals into the cell. It has been suggested that distinct membrane domains known as glycosphingolipid-enriched microdomains or membrane rafts are central for receptor clustering (Simons and Ikonen, 1997) . Rafts are organized membrane domains mainly composed of glycosphingolipids, sphingomyelin, cholesterol and specific membrane proteins (Simons and Ikonen, 1997; Brown and London, 1998) . Several studies indicated that rafts are required to cluster CD95 and to recruit FADD, caspase 8 and 3 to CD95 upon stimulation (Grassme et al., 2001b Hueber et al., 2002; Scheel-Toellner et al., 2002; Delmas et al., 2003; Aouad et al., 2004; Eramo et al., 2004) . Accordingly, disruption of rafts prevented CD95-induced apoptosis, at least in most cells (Grassme et al., 2001b; Cremesti et al., 2001; Hueber et al., 2002; Scheel-Toellner et al., 2002) . Likewise, a recent study by Delmas et al. (2004) reported that DR4 and DR5 translocate into rafts upon stimulation. Disruption of rafts by cholesterol-extracting reagents inhibited TRAIL-induced cell death (Delmas et al., 2004) . Although these studies clearly indicate the significance of rafts for death receptor signaling, they do not provide a mechanism how rafts mediate death receptor clustering and reorganization of the death-inducing signalosome. We and others elaborated in the last years a mechanism how rafts can be transformed into a signaling unit. These studies demonstrated that stimulation of CD95 results in an activation of the acid sphingomyelinase (ASM) and a concomitant release of ceramide in the outer leaflet of the cell membrane (Cremesti et al., 2001; Grassme et al., 2001a Grassme et al., , b, 2003 . Ceramide molecules spontaneously associate and form ceramide-enriched membrane microdomains. These microdomains tend to fuse and form large ceramideenriched membrane platforms (Grassme et al., 2001a (Grassme et al., , b, 2003 Nurminen et al., 2002) . Ceramide-enriched membrane platforms serve to trap and cluster CD95 molecules, an event that is prerequisite for efficient signaling via this receptor and the induction of apoptosis (Cremesti et al., 2001; Grassme et al., 2001a Grassme et al., , b, 2003 . A similar model applies to the CD40 (Grassme et al., 2002; Bock and Gulbins, 2003) and Fcgreceptor (Abdel Shakor et al., 2004) .
However, it is unknown whether ceramide-enriched membrane platforms are also involved in signaling of other death receptor molecules. Even more important, molecular mechanisms activating the ASM by death receptors remain to be identified.
In the present study, we investigated the role of ASM and ceramide for TRAIL-induced apoptosis. Moreover, we suggest that activation of the ASM is mediated by oxidation and dimerization of the enzyme at least after DR5 and CD95 stimulation. We also tested whether a pharmacological induction of ceramideenriched membrane platforms sensitizes tumor cells to TRAIL-induced apoptosis. We show that stimulated splenocytes as well as a variety of tumor cell lines respond to TRAIL treatment with an activation of the ASM, ceramide release, the formation of ceramideenriched membrane platforms, DR5-clustering within these ceramide platforms, and apoptosis. Acid sphingomyelinase-deficient splenocytes failed to respond to TRAIL, while low concentrations of natural C 16 -ceramide restored DR5-clustering and apoptosis in these cells.
Results
To test whether the ASM and ceramide-enriched membrane platforms are involved in TRAIL-induced apoptosis, we investigated the effects of TRAIL in ASM-positive and ASM-deficient splenocytes. The splenocytes were activated by PHA and IL-2 for 72 h to induce expression of DR5. Expression of the receptor was confirmed by FACS and did not significantly differ between ASM-positive and -negative splenic T cells (Figure 1a ) after PHA/IL-2 stimulation. For comparison, we also determined the expression level of DR5 in several cell lines, that is BJAB-lymphocytes, A549 lung epithelial cells and L929 murine fibroblasts. The FACS data indicate that all cells express similar amounts of DR5 on the cell surface compared to background (secondary antibody only). Incubation of the cells with TRAIL resulted in rapid induction of apoptosis in ASM-positive T splenocytes, while deficiency of the ASM prevented TRAIL-induced apoptosis (Figure 1b) . Induction of apoptosis upon TRAIL stimulation was confirmed by simultaneous staining of the cells with FITC-Annexin V and propidium iodide (Figure 1c) . These studies show a dose-dependent induction of apoptosis by TRAIL, while no significant necrosis was observed. These data establish a central role of the ASM for the induction of apoptosis by TRAIL.
To define the function of the ASM for TRAILinduced apoptosis, we tested whether TRAIL activates the ASM and triggers a release of ceramide. We stimulated peripheral T splenocytes, BJAB lymphocytes, A549-lung epithelial cells and L929-murine fibroblasts with TRAIL and determined the activity of the ASM in cell lysates. Tumor necrosis factor-related apoptosisinducing ligand induced a rapid activation of the ASM peaking approximately 10 min (for T splenocytes and BJAB) or 20-30 min (for L929 and A549) after stimulation and declining thereafter (Figure 2a-d) .
Activation of the ASM correlated with a release of ceramide in BJAB, A549, L929-cells and ASM-positive splenocytes, while ASM-deficient splenocytes failed to respond to TRAIL with an increase of ceramide ( Figure  3a -c). Cellular ceramide was determined by FACSanalysis ( Figure 3a ) employing monoclonal anti-ceramide antibodies to detect ceramide on the cell surface as well as by the previously published DAG-kinase assay ( Figure 3b ) (Gulbins and Kolesnick, 2000) . Confocal microscopy studies on ex vivo splenocytes confirmed the release of ceramide in ASM-positive splenocytes by TRAIL, while no release was observed in ASM-deficient splenocytes ( Figure 3c ).
More importantly, the confocal microscopy studies revealed that TRAIL triggered the formation of ceramide-enriched membrane platforms in ASM-positive splenocytes (Figure 3c ). Acid sphingomyelinasedeficient splenocytes did not exhibit such platforms (Figure 3c ).
Previous studies indicated that ceramide-enriched membrane platforms serve to reorganize activated receptor molecules in the plasma membrane (Grassme et al., 2001a (Grassme et al., , b, 2002 Cremesti et al., 2001; Abdel Shakor et al., 2004) . We, therefore, investigated whether (Figure 4e ). We like to point out that TRAIL did not alter total expression of DR5 as determined by FACS analysis (Figure 4f ) and the increase of the DR5 signal in the confocal microscopy studies (Figure 4a ) is most likely caused by a massive reorganization and concentration of DR5 in the platform and, thus, in the analysis level of the microscope.
To determine the significance of DR5 clustering in ceramide-enriched membrane domains for TRAILinduced apoptosis, we investigated whether the addition of natural C 16 -ceramide to ASM-deficient splenocytes converts the resistance of these cells to TRAIL-induced apoptosis. As demonstrated in Figure 5a small amounts of natural C 16 -ceramide were sufficient to restore sensitivity of ASM-deficient splenic T cells to TRAILinduced apoptosis, although the cells lack ASM activity. A dose-response analysis reveals that already 0.1 mM C 16 -ceramide are able to sensitize ASM-deficient T cells to TRAIL and the maximum sensitization was already observed with 0.5 mM C 16 -ceramide ( Figure 5a ). Low doses of C 16 -ceramide did not trigger apoptosis by themselves. Control experiments confirmed the formation of ceramide-enriched membrane platforms after addition of exogenous C 16 -ceramide ( Figure 5b ). Next, we studied whether clustering of DR5 alone is sufficient to induce apoptosis in ASM-deficient cells. To this end, Ceramide mediates TRAIL-induced apoptosis CA Dumitru and E Gulbins we stimulated ASM-deficient splenocytes with low physiological or very high doses of aggregated TRAIL-ligand, respectively. While ASM-deficient splenic T cells were resistant to doses up to 100 ng/ml of TRAIL, they died by apoptosis after treatment with high doses of aggregated TRAIL (Figure 5c ) indicating that forced, artificial clustering of DR5 in ASMdeficient cells is sufficient to overcome the genetic defect of the ASM. Next, we aimed to identify molecular mechanisms of ASM-activation by TRAIL. Previous studies demonstrated a role of reactive oxygen species in the induction apoptosis by CD95 (Gulbins et al., 1996; Liu et al., 1996; Um et al., 1996; Yin, 2005; Reinehr et al., 2005) . To test the hypothesis that the ASM is regulated by a redoxmechanism in vivo, we determined the release of reactive oxygen species (ROS) upon stimulation of BJAB or splenocytes with TRAIL for 1 min. The results indicate a very rapid release of ROS upon activation of the cells with TRAIL, which was prevented by preincubation with the antioxidants Tiron or N-acetylcysteine, respectively (Figure 6a ). Tiron and N-acetylcysteine also blocked activation of the ASM in BJAB as well as splenocytes upon stimulation with TRAIL (Figure 6b ), suggesting that a redox mechanism is involved in regulation of the ASM. Inhibition of the ASM by Tiron or N-acetylcysteine, respectively, correlated with an inhibition of ceramide release and the formation of ceramide-enriched membrane platforms triggered by TRAIL (Figure 6c) . Likewise, the two antioxidants also reduced TRAIL-induced apoptosis (Figure 6d ). Control experiments confirmed that neither Tiron nor Nacetylcysteine affected binding of TRAIL or anti-CD95 antibodies, respectively (not shown).
Our data demonstrate that ceramide-enriched membrane platforms are required for TRAIL-signaling under physiological conditions that are characterized by low nanomolar TRAIL concentrations. The data displayed in Figure 5a and b showing that C 16 -ceramide addition or forced clustering of DR5, respectively, restore TRAIL-induced apoptosis in ASM-deficient cells indicate that an interaction of TRAIL with DR5-trimers is not sufficient to trigger death. These data suggest that clustering of receptor molecules is critical to initiate apoptosis. However, very low doses of TRAIL are unable to induce activation of the ASM and formation of ceramide-enriched membrane platforms, although the ligand binds to DR5 and transforms the receptor into the active DR5-ligand complex. This suggests that below a certain threshold concentration TRAIL is unable to stimulate cells. We, therefore, hypothesized that a pharmacological induction of ceramide-enriched membrane platforms might be sufficient to amplify the effect of very low concentrations of TRAIL binding to DR5. To test this concept, we treated a panel of tumor cells with 10-100 ng/ml TRAIL, 2 mM C 16 -ceramide or a combination of both. C 16 -ceramide addition resulted in the formation of ceramide-enriched membrane platforms (not shown), but neither low dose (10-25 ng/ml) TRAIL nor 2 mM C 16 -ceramide alone had any apoptotic effect on the tumor cells after 24 h incubation (Figure 7a and b) . In contrast, the combination of 2 mM C 16 -ceramide and low dose TRAIL killed the tumor cells as efficient as high doses of TRAIL (Figure 7a and b) . This concept suggests that any drug or treatment inducing ceramide-enriched membrane Ceramide mediates TRAIL-induced apoptosis CA Dumitru and E Gulbins platforms amplifies the effects of TRAIL on tumor cells and may permit the usage of a TRAIL-dose that is without biological effect per se.
Discussion
In the present manuscript, we identify the ASM as a novel key molecule for the induction of apoptosis by TRAIL/DR5. We characterize a molecular mechanism of ASM activation in vivo and show that the enzyme is directly or indirectly regulated via a redox mechanism. We demonstrate that TRAIL very rapidly induces a stimulation of the ASM to release ceramide that forms large ceramide-enriched membrane domains serving to trap and cluster DR5. The reorganization of DR5 in the cell membrane into ceramide-enriched membrane domains seems to be required for the induction of apoptosis by DR5, as cells lacking ASM and, thus, unable to release ceramide after stimulation, are resistant to DR5-induced apoptosis, while addition of natural ceramide restored apoptosis. Furthermore, very low doses of TRAIL that are insufficient to trigger cell death by themselves are converted into potent inducers of apoptosis upon formation of ceramide-enriched membrane platforms after treatment of normal or tumor cells with C 16 -ceramide. These findings indicate that the release of ceramide and not just the consumption of sphingomyelin is required for DR5-induced apoptosis. The experiments further suggest that clustering of DR5 trimers in ceramide-enriched membrane platforms is required for induction of apoptosis by DR5. This concept is consistent with findings on CD95 that demonstrated an activation of the ASM and the formation of ceramide-enriched membrane platforms before formation of the DISC and execution of apoptosis .
Our results suggest that a redox mechanism mediates activation of the ASM upon stimulation via death receptors. This notion is consistent with a previous biochemical study (Qiu et al., 2003) indicating that oxidation of purified ASM at cysteine 629 results in stimulation and a disulfide bond-mediated dimerization A central role of ROS for the induction of apoptosis by CD95 has been previously reported (Gulbins et al., 1996; Um et al., 1996) and was recently confirmed by several studies (Reinehr et al., 2005; Yin, 2005) . Experiments on hepatocytes demonstrated that an inhibitor of the ASM blocks the release of ROS suggesting that ROS functions downstream of the ASM (Reinehr et al., 2005; Yin, 2005) . However, this is not in contrast to the present data, as we have previously shown that CD95 primarily induces a very weak stimulation of caspase 8 that results within seconds in the translocation and activation of the ASM and the formation of ceramide-enriched membrane domains that cluster CD95 . Thus, the ASM functions in a feed forward loop to amplify signaling via death receptors and a blockade of this forward loop by inhibition of the ASM would also prevent the release of ROS.
It is interesting to note that although the activity of the ASM and the release of ceramide were lower in T splenocytes than in the tested cell lines, the number of cells presenting ceramide-enriched membrane platforms and DR5 cluster induced by TRAIL were very similar. This suggests that a threshold of ceramide in the plasma membrane is sufficient to mediate DR5 clustering and apoptosis.
Our data indicate that the central function of ASM and ceramide for the initiation of apoptosis is not restricted to CD95 and TNF, but is also required for death by DR5 and, very likely, other proapoptotic members of the TNF/NGF-factor receptor family. This suggests that the formation of ceramide-enriched membrane platforms upon ASM activation is a general mechanism to initiate signaling of the TNF/NGF-factor receptor family. Recent data by Voelkel-Johnson et al. (2005) confirmed the notion that ceramide is involved in TRAIL-induced death. However, these studies on colon cancer cells revealed a later increase of ceramide by TRAIL, which is consistent with a reduced sensitivity and a delayed time course of apoptosis (only 20% apoptosis 24 h after stimulation with 10 ng/ml TRAIL) in these cells compared to lymphocytes.
Several studies in the last years linked the formation of ceramide-enriched membrane platforms to the induction of cell death. For instance, apoptosis triggered by cisplatin or doxorubicin requires functional expression of the ASM, the release of ceramide and the formation of ceramide-enriched membrane platforms (Andrieu-Abadie et al., 1999; Delpy et al., 1999; Morita et al., 2000; Lacour et al., 2004) . Very similar results were described for induction of apoptosis by CD95 as shown by many groups employing a variety of different cells (Cremesti et al., 2001; Grassme et al., 2001a Grassme et al., , b, 2003 Fanzo et al., 2003) . Furthermore, developmental apoptosis of oocytes and neutrophils is delayed by deficiency of the ASM (Morita et al., 2000; ScheelToellner et al., 2002 ScheelToellner et al., , 2004a and the formation of ceramide-enriched membrane platforms constitutes one of the earliest events linked to the induction of apoptosis in these cells. We have shown that infection of mammalian epithelial and endothelial cells or fibroblasts with Staphylococus aureus or Pseudomonas aeruginosa, respectively, induces apoptosis of the host cell via formation of ceramide-enriched membrane platforms that may serve to reorganize cellular receptors and signaling molecules involved in the induction of apoptosis by the pathogens (Grassme et al., 1997 Esen et al., 2001) . Most of these studies suggested that the formation of ceramide-enriched membrane platforms is initiated within small cholesterol-and sphingolipid-enriched membrane rafts. The notion that rafts are important for the induction of apoptosis is supported by several recent studies demonstrating that destruction of these membrane rafts prevents CD95 clustering, recruitment of FADD and caspase 8 and apoptosis by CD95 (Cremesti et al., 2001; Grassme et al., 2001b; Hueber et al., 2002; Scheel-Toellner et al., 2002) . However, our studies go far beyond the finding that rafts are involved in apoptosis and suggest a mechanism how small rafts in resting cells can be transformed into a signaling unit that transmits signals from out to inside of the cell. The generation of ceramide within rafts may result in the formation of ceramide-rich microdomains, which are formed by the tendency of ceramide to self-associate. Ceramide-rich microdomains seem to spontaneously fuse to a large ceramide-enriched membrane platform (Nurminen et al., 2002) serving to cluster receptor molecules. This certainly does not exclude that other receptors employ different mechanisms to cluster and/or transform rafts into a larger membrane platform.
Our studies suggest a novel mechanism how the proapoptotic potential of TRAIL might be employed to kill tumor cells without affecting normal cells. We show that neither low doses of TRAIL nor of C 16 -ceramide are able to kill tumor cells or ex vivo splenocytes. In addition, low doses of TRAIL are without effect on the liver after intravenous injection (C Dumitru and E Gulbins, unpublished) . In contrast, the combination of both stimuli was able to kill a panel of tumor cells with extremely high efficiency and almost all tumor cells were killed within 24 h after combined treatment.
The transfer of this concept to a clinical situation predicts that very low doses of TRAIL and an inducer of local ceramide are sufficient to kill tumor cells, while TRAIL at this dose will be without effect in other organs. Candidates for local production of ceramide are ionizing radiation, UV-light, locally applied cytostatic drugs or heat. A timely and locally coordinated production of ceramide in the tumor tissues with the application of very low doses systemic TRAIL may permit an efficient treatment of at least some human malignancies.
Placid, NY, USA; polyclonal rabbit anti-CD95 antibodies from Anaspec Inc., San Jose, CA, USA. Monoclonal anticeramide antibodies were from Sigma and hamster anti-mouse CD3e were purchased from BD-PharMingen, San Diego, CA, USA. All fluorescent secondary antibodies (FITC-goat antimouse IgM, Cy3-goat anti-armenian hamster IgG, Cy3-donkey anti-rabbit IgG and Cy5-donkey anti-rabbit IgG) were from Jackson Immunoresearch, West Grove, PA, USA. Reactive oxygen species were inhibited by the antioxidants Tiron (1 mM, Sigma) and N-acetylcysteine (1-10 mM, Sigma). Tiron or N-acetylcysteine were added to the cells 20 min before stimulation with TRAIL or anti-CD95 CH11.
Isolation of murine spleen T cells
Single cell suspension of total splenocytes was obtained by mechanical disruption of the spleen, followed by Ficoll density-centrifugation to remove erythrocytes and cellular debris. T-cell purification was performed using MACS MHC class II MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the protocol provided by the manufacturer. The cells were maintained in RPMI-1640 supplemented as above. The cells were stimulated with 10 mg/ ml phytohemagglutinine (PHA, Sigma) and 5 Units/ml murine interleukin-2 (IL-2; Roche Molecular Biochemicals, Penzberg, Germany) for 72 h prior to treatment.
Immunocytochemistry assays
Cells were treated with TRAIL as indicated, washed once in HEPES/saline (H/S; 132 mM NaCl, 20 mM HEPES (pH 7.4), 5 mM KCl, 1 mM CaCl 2 , 0.7 mM MgCl 2 , 0.8 mM MgSO 4 ) and fixed in 2% PFA in PBS (pH 7.4) for 15 min. Cells were washed once in H/S and incubated with the indicated primary antibodies for 45 min at room temperature. Anti-DR5 and anti-CD3e-antibodies were diluted 1:100 in H/S, anti-ceramide-antibodies were diluted 1:50. The samples were washed again and incubated with the respective fluorescent secondary antibodies for 30 min at room temperature. All secondary antibodies were diluted 1:1000 in H/S. Cells were finally washed two times and mounted in moviol.
Fluorescence microscopy was performed using an inverse LEICA DMIRE 2 microscope. Digitalized pictures were collected and processed using the Q-FLUORO program (Leica, Germany). Laser scanning microscopy was performed on a LEICA TSP2 module linked to the LEICA DMIRE 2 microscope.
Acid sphingomyelinase activity Acid sphingomyelinase activity was measured as previously described (Gulbins and Kolesnick, 2000) . Splenic T cells or tumor cells were incubated with 5 or 100 ng/ml TRAIL, respectively, for the indicated times. The cells were then pelleted for 5 min at 1500 r.p.m. and lysed in a buffer containing 0.1% Triton X-100 and 50 mM sodium acetate (pH 5.0) for 10 min on ice followed by each three freeze/ thawing and sonication cycles. The cell lysates were immediately incubated with 0.05 mCi per sample 14 C-labeled sphingomyelin (2 GBq/mmol; MP-Biomedicals, Irvine, CA, USA) for 30 min at 371C. To this end, the substrate 14 C-labeled sphingomyelin was dried under vacuum, resuspended in 0.1% Triton X-100 and 50 mM sodium acetate (pH 5.0) and sonicated in a bath sonicator to promote the formation of liposomes. The reaction was terminated by extraction in chloroform:methanol (2:1, v/v). The samples were centrifuged for 10 min at 14000 r.p.m. and an aliquot of the aqueous phase was measured by liquid scintillation counting to quantify released phosphorylcholine. This method results in hydrolysis of less than 20% (range of 2% to maximal 20%) of 14 C-labeled sphingomyelin and is therefore suitable for a broad range of cells.
Apoptosis assays
Cell viability was determined both by Trypan blue exclusion and FACS analysis. For FACS analysis, cells were stained with FITC-Annexin V or FITC-Annexin V plus propidium iodide (100 ng/ml) according to the manufacturer's instructions (Roche Molecular Biochemicals). FITC-Annexin V-binding indicates apoptotic cells and was quantified employing a FACS Calibur flow cytometer (Beckton Dickinson, San Jose, CA, USA).
C 16 -ceramide reconstitution ASM-deficient splenocytes and tumor cells were incubated with 1 or 2 mM C 16 -ceramide (Biomol, PA, USA), respectively, for 10 min before TRAIL treatment. C 16 -ceramide stock solution (1 mM) was prepared in 10% n-octylglucopyranoside and sonicated 10 min on ice before use. TRAIL was added at the indicated concentration and cell viability was determined by Trypan blue exclusion and FACS analysis.
Ceramide measurement
Ceramide was determined by FACS analysis and the DAGkinase assay. For FACS analysis, activated T splenocytes were left untreated or treated with 5 ng/ml TRAIL for 10 min and fixed in 2% PFA. The ceramide staining was performed using anti-ceramide antibodies clone 15B4 for 60 min, followed by a 20 min staining with FITC-goat anti-mouse IgM antibody and FACS analysis.
To determine ceramide by the DAG-kinase assay, cells were extracted in CHCl 3 :CH 3 OH:1 N HCl (100:100:1), the organic phase was collected, dried and diacylglycerol degraded by incubation of the samples in 0.1 N methanolic KOH at 371C for 60 min. After re-extraction the lower phase was dried and resuspended in 20 ml of a detergent solution consisting of 7.5% (w/v) n-octylglucopyranoside and 5 mM cardiolipin in 1 mM DETAPAC (diethylenetriamine pentaacetic acid). To promote the formation of micelles the samples were sonicated for 10 min in a bath sonicator. To start the kinase reaction 50 ml of a buffer consisting of 0.1 M imidazole/HCl (pH 6.6), 0.1 M NaCl, 25 mM MgCl 2 and 2 mM EDTA, 2.8 mM DTT, 5 mM ATP, 10 mCi [ 32 P]gATP and 10 ml diluted DAG kinase (dilution buffer: 1 mM DETAPAC (pH 6.6), 0.01 M imidazole/HCl) were added and the samples were incubated for 30 min at room temperature. The kinase reaction was stopped by extraction of the samples with 1 ml CHCl 3 :CH 3 OH:1 N HCl (100:100:1), 170 ml buffered saline solution (135 mM NaCl, 1.5 mM CaCl 2 , 0.5 mM MgCl 2 , 5.6 mM Glucose, 10 mM HEPES, pH 7.2) and 30 ml of a 100 mM EDTA-solution. The lower phase was collected, dried and dissolved in 20 ml CHCl 3 :CH 3 OH (1:1). Lipids were separated on a Silica G60 TLC plate with CHCl 3 :CH 3 OH:CH 3 COOH (65:15:5), the plates were dried and analysed by autoradiography. Ceramide-spots were identified by co-migration with a C 16 -ceramide 1-phosphate standard, scrapped from the plate and quantified by liquid scintillation counting. Comparison with a standard curve employing C 16 -ceramide as substrate permitted the determination of ceramide amounts.
Formation of reactive oxygen species Cells were stimulated with TRAIL or left untreated in the presence or absence of antioxidants. Cells were lysed with a buffer containing 0.1% sodium dodecyl sulfate, 0.5% deoxycholic acid, 1% Triton X-100, 10 mM EDTA, 25 mM HEPES pH 7.3, 10 mM sodium pyrophosphate, 10 mM sodium fluoride, 125 mM NaCl, and 1 mg/ml oxidized cytochrome c (Sigma) as previously described (Gulbins et al., 1996) . Samples were immediately transferred to a cuvette, covered with mineral oil and absorbance at 550 nm was determined.
